{"pmid":32405974,"pmcid":"PMC7220847","title":"Organ function support in patients with coronavirus disease 2019: Tongji experience.","text":["Organ function support in patients with coronavirus disease 2019: Tongji experience.","Coronavirus disease 2019 (COVID-19) is a highly contagious disease and a serious threat to human health. COVID-19 can cause multiple organ dysfunction, such as respiratory and circulatory failure, liver and kidney injury, disseminated intravascular coagulation, and thromboembolism, and even death. The World Health Organization reports that the mortality rate of severe-type COVID-19 is over 50%. Currently, the number of severe cases worldwide has increased rapidly, but the experience in the treatment of infected patients is still limited. Given the lack of specific antiviral drugs, multi-organ function support treatment is important for patients with COVID-19. To improve the cure rate and reduce the mortality of patients with severe- and critical-type COVID-19, this paper summarizes the experience of organ function support in patients with severe- and critical-type COVID-19 in Optical Valley Branch of Tongji Hospital, Wuhan, China. This paper systematically summarizes the procedures of functional support therapies for multiple organs and systems, including respiratory, circulatory, renal, hepatic, and hematological systems, among patients with severe- and critical-type COVID-19. This paper provides a clinical reference and a new strategy for the optimal treatment of COVID-19 worldwide.","Front Med","Li, Yong","He, Fan","Zhou, Ning","Wei, Jia","Ding, Zeyang","Wang, Luyun","Chen, Peng","Guo, Shuiming","Zhang, Binhao","Wan, Xiaoning","Zhu, Wei","32405974"],"abstract":["Coronavirus disease 2019 (COVID-19) is a highly contagious disease and a serious threat to human health. COVID-19 can cause multiple organ dysfunction, such as respiratory and circulatory failure, liver and kidney injury, disseminated intravascular coagulation, and thromboembolism, and even death. The World Health Organization reports that the mortality rate of severe-type COVID-19 is over 50%. Currently, the number of severe cases worldwide has increased rapidly, but the experience in the treatment of infected patients is still limited. Given the lack of specific antiviral drugs, multi-organ function support treatment is important for patients with COVID-19. To improve the cure rate and reduce the mortality of patients with severe- and critical-type COVID-19, this paper summarizes the experience of organ function support in patients with severe- and critical-type COVID-19 in Optical Valley Branch of Tongji Hospital, Wuhan, China. This paper systematically summarizes the procedures of functional support therapies for multiple organs and systems, including respiratory, circulatory, renal, hepatic, and hematological systems, among patients with severe- and critical-type COVID-19. This paper provides a clinical reference and a new strategy for the optimal treatment of COVID-19 worldwide."],"journal":"Front Med","authors":["Li, Yong","He, Fan","Zhou, Ning","Wei, Jia","Ding, Zeyang","Wang, Luyun","Chen, Peng","Guo, Shuiming","Zhang, Binhao","Wan, Xiaoning","Zhu, Wei"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405974","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s11684-020-0774-9","keywords":["covid-19","organ function support","severe and critical type"],"locations":["Optical Valley","Tongji Hospital","Wuhan","China","Tongji"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666950579818070018,"score":9.490897,"similar":[{"pmid":32219882,"title":"Controversial treatments: An updated understanding of the coronavirus disease 2019.","text":["Controversial treatments: An updated understanding of the coronavirus disease 2019.","An outbreak of severe acute respiratory syndrome-related coronavirus 2 infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among coronavirus disease 2019 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, and chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system, and extracorporeal membrane oxygenation based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively.","J Med Virol","Zhang, Cantong","Huang, Shaoying","Zheng, Fengping","Dai, Yong","32219882"],"abstract":["An outbreak of severe acute respiratory syndrome-related coronavirus 2 infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among coronavirus disease 2019 patients, we should not ignore the complications, such as RNAaemia, acute respiratory distress syndrome, and multiple organ dysfunction. To help understand the advantages and limitations of differential treatments, we provide a timely review and discuss the complications and corresponding major treatments, especially controversial ones such as antiviral therapy (remdesivir, ribavirin, and chloroquine), glucocorticoid therapy, extracorporeal support including an artificial liver system, and extracorporeal membrane oxygenation based on available evidence. As a result, we suggest that antiviral therapy and organ function support are vital to reduce mortality for mild patients and critical patients, respectively."],"journal":"J Med Virol","authors":["Zhang, Cantong","Huang, Shaoying","Zheng, Fengping","Dai, Yong"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219882","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1002/jmv.25788","keywords":["covid-19","sars-cov-2","coronavirus","literature review","pneumonia","treatment"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["remdesivir","Chloroquine","Ribavirin"],"topics":["Treatment"],"weight":1,"_version_":1666138492299640833,"score":213.74449},{"pmid":32450165,"title":"Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.","text":["Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review.","Human coronaviruses, especially COVID-19, is an emerging pandemic infectious disease with high morbidity and mortality. Coronaviruses are associated with comorbidities, along with the symptoms of it. SARS-CoV-2 is one of the highly pathogenic coronaviruses that causes a high death rate compared to the SARS-CoV and MERS. In this review, we focused on the mechanism of coronavirus with comorbidities and impairment in multi-organ function. The main dysfunction upon coronavirus infection is damage to alveolar and acute respiratory failure. It is associated with the other organ damage such as cardiovascular risk via an increased level of hypertension through ACE2, gastrointestinal dysfunction, chronic kidney disease, diabetes mellitus, liver dysfunction, lung injury, CNS risk, ocular risks such as chemosis, conjunctivitis, and conjunctival hyperemia, cancer risk, venous thromboembolism, tuberculosis, aging, and cardiovascular dysfunction and reproductive risk. Along with this, we have discussed the immunopathology and coronaviruses at a molecular level and therapeutic approaches for the coronavirus infection. The comorbidities and multi-organ failure of COVID-19 have been explained at a molecular level along with the base of the SARS-CoV and MERS-CoV. This review would help us to understand the comorbidities associated with the coronaviruses with multi-organ damage.","Life Sci","KaviyarasiRenu","Prasanna, Pureti Lakshmi","Abilash, V G","32450165"],"abstract":["Human coronaviruses, especially COVID-19, is an emerging pandemic infectious disease with high morbidity and mortality. Coronaviruses are associated with comorbidities, along with the symptoms of it. SARS-CoV-2 is one of the highly pathogenic coronaviruses that causes a high death rate compared to the SARS-CoV and MERS. In this review, we focused on the mechanism of coronavirus with comorbidities and impairment in multi-organ function. The main dysfunction upon coronavirus infection is damage to alveolar and acute respiratory failure. It is associated with the other organ damage such as cardiovascular risk via an increased level of hypertension through ACE2, gastrointestinal dysfunction, chronic kidney disease, diabetes mellitus, liver dysfunction, lung injury, CNS risk, ocular risks such as chemosis, conjunctivitis, and conjunctival hyperemia, cancer risk, venous thromboembolism, tuberculosis, aging, and cardiovascular dysfunction and reproductive risk. Along with this, we have discussed the immunopathology and coronaviruses at a molecular level and therapeutic approaches for the coronavirus infection. The comorbidities and multi-organ failure of COVID-19 have been explained at a molecular level along with the base of the SARS-CoV and MERS-CoV. This review would help us to understand the comorbidities associated with the coronaviruses with multi-organ damage."],"journal":"Life Sci","authors":["KaviyarasiRenu","Prasanna, Pureti Lakshmi","Abilash, V G"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32450165","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.lfs.2020.117839","keywords":["covid-19","comorbidities","multi-organ failure and immunopathology","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667785213891051520,"score":196.61397},{"pmid":32408391,"title":"Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.","text":["Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.","Most severe manifestations of COVID-19 cases, such as multiple organ failure and death, have been linked to coagulation dysfunction markers, such as platelet reduction and increases in prothrombin time, fibrin degradation products and, mainly, D-dimer [1]. A recent paper by Tang et al. [2] in this journal reported that heparin treatment reduced mortality of COVID-19 patients with elevated D-dimer; similar preliminary results have been reported elsewhere [3]. A mounting body of evidence shows that SARS-CoV-2 causes a \"cytokine storm\" [1,4] that activates the coagulation cascade, leading to thrombosis. Similar to the findings in severe sepsis, generalized deposition of intravascular thrombi compromises the blood supply of several organs, leading to organ failure [5].","J Thromb Haemost","Menezes-Rodrigues, Francisco Sandro","Padrao Tavares, Jose Gustavo","Pires de Oliveira, Marcelo","Guzella de Carvalho, Rafael","Ruggero Errante, Paolo","Omar Taha, Murched","Fagundes, Djalma Jose","Caricati-Neto, Afonso","32408391"],"abstract":["Most severe manifestations of COVID-19 cases, such as multiple organ failure and death, have been linked to coagulation dysfunction markers, such as platelet reduction and increases in prothrombin time, fibrin degradation products and, mainly, D-dimer [1]. A recent paper by Tang et al. [2] in this journal reported that heparin treatment reduced mortality of COVID-19 patients with elevated D-dimer; similar preliminary results have been reported elsewhere [3]. A mounting body of evidence shows that SARS-CoV-2 causes a \"cytokine storm\" [1,4] that activates the coagulation cascade, leading to thrombosis. Similar to the findings in severe sepsis, generalized deposition of intravascular thrombi compromises the blood supply of several organs, leading to organ failure [5]."],"journal":"J Thromb Haemost","authors":["Menezes-Rodrigues, Francisco Sandro","Padrao Tavares, Jose Gustavo","Pires de Oliveira, Marcelo","Guzella de Carvalho, Rafael","Ruggero Errante, Paolo","Omar Taha, Murched","Fagundes, Djalma Jose","Caricati-Neto, Afonso"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408391","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/jth.14902","topics":["Treatment"],"weight":1,"_version_":1666802845275389952,"score":172.67497},{"pmid":32451729,"title":"Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.","text":["Corticosteroid treatment in severe COVID-19 pneumonia: two cases and literature review.","Coronavirus disease 2019 (COVID-19) pneumonia, firstly reported in Wuhan, Hubei province, China, has rapidly spread around the world with high mortality rate among critically ill patients. The use of corticosteroids in COVID-19 remains a major controversy. Available evidences are inconclusive. According to WHO guidance, corticosteroids are not recommended to be used unless for another reason. Chinese Thoracic Society (CTS) proposes an expert consensus statement that suggests taking a prudent attitude of corticosteroid usage. In our clinical practice, we do not use corticosteroids routinely; only low-to-moderate doses of corticosteroids were given to several severely ill patients prudently. In this paper, we will present two confirmed severe COVID-19 cases admitted to isolation wards in Optical Valley Campus of Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology. We will discuss questions related to corticosteroids usages.","Clin Rheumatol","Dai, Jinghong","Xiong, Yali","Li, Hui","Qian, Yajun","Xu, Ying","Xu, Qingqing","Yan, Xin","Tang, Jian","32451729"],"abstract":["Coronavirus disease 2019 (COVID-19) pneumonia, firstly reported in Wuhan, Hubei province, China, has rapidly spread around the world with high mortality rate among critically ill patients. The use of corticosteroids in COVID-19 remains a major controversy. Available evidences are inconclusive. According to WHO guidance, corticosteroids are not recommended to be used unless for another reason. Chinese Thoracic Society (CTS) proposes an expert consensus statement that suggests taking a prudent attitude of corticosteroid usage. In our clinical practice, we do not use corticosteroids routinely; only low-to-moderate doses of corticosteroids were given to several severely ill patients prudently. In this paper, we will present two confirmed severe COVID-19 cases admitted to isolation wards in Optical Valley Campus of Tongji hospital, Tongji Medical College, Huazhong University of Science and Technology. We will discuss questions related to corticosteroids usages."],"journal":"Clin Rheumatol","authors":["Dai, Jinghong","Xiong, Yali","Li, Hui","Qian, Yajun","Xu, Ying","Xu, Qingqing","Yan, Xin","Tang, Jian"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451729","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s10067-020-05172-7","keywords":["covid-19","corticosteroids","hrct","severe covid-19 pneumonia"],"locations":["Wuhan","Hubei","China","Tongji"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667881798401523712,"score":169.15225},{"pmid":32454500,"title":"Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.","text":["Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.","Critically ill COVID-19 patients are generally admitted to the ICU for respiratory insufficiency which can evolve into a multiple-organ dysfunction syndrome requiring extracorporeal organ support. Ongoing advances in technology and science and progress in information technology support the development of integrated multi-organ support platforms for personalized treatment according to the changing needs of the patient. Based on pathophysiological derangements observed in COVID-19 patients, a rationale emerges for sequential extracorporeal therapies designed to remove inflammatory mediators and support different organ systems. In the absence of vaccines or direct therapy for COVID-19, extracorporeal therapies could represent an option to prevent organ failure and improve survival. The enormous demand in care for COVID-19 patients requires an immediate response from the scientific community. Thus, a detailed review of the available technology is provided by experts followed by a series of recommendation based on current experience and opinions, while waiting for generation of robust evidence from trials.","Blood Purif","Ronco, Claudio","Bagshaw, Sean M","Bellomo, Rinaldo","Clark, William R","Husain-Syed, Faeq","Kellum, John A","Ricci, Zaccaria","Rimmele, Thomas","Reis, Thiago","Ostermann, Marlies","32454500"],"abstract":["Critically ill COVID-19 patients are generally admitted to the ICU for respiratory insufficiency which can evolve into a multiple-organ dysfunction syndrome requiring extracorporeal organ support. Ongoing advances in technology and science and progress in information technology support the development of integrated multi-organ support platforms for personalized treatment according to the changing needs of the patient. Based on pathophysiological derangements observed in COVID-19 patients, a rationale emerges for sequential extracorporeal therapies designed to remove inflammatory mediators and support different organ systems. In the absence of vaccines or direct therapy for COVID-19, extracorporeal therapies could represent an option to prevent organ failure and improve survival. The enormous demand in care for COVID-19 patients requires an immediate response from the scientific community. Thus, a detailed review of the available technology is provided by experts followed by a series of recommendation based on current experience and opinions, while waiting for generation of robust evidence from trials."],"journal":"Blood Purif","authors":["Ronco, Claudio","Bagshaw, Sean M","Bellomo, Rinaldo","Clark, William R","Husain-Syed, Faeq","Kellum, John A","Ricci, Zaccaria","Rimmele, Thomas","Reis, Thiago","Ostermann, Marlies"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454500","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1159/000508125","keywords":["continuous renal replacement therapies","cytokine removal","extracorporeal organ support","hemoadsorption","hemoperfusion"],"topics":["Treatment"],"weight":1,"_version_":1667983494595215360,"score":166.69841}]}